The impact of multimodal physiotherapy in an interdisciplinary setting for the management of women with persistent pelvic pain and pelvic floor tension myalgia

Figures & data

Table 1. Participant demographics.

Demographics	Consented, n = 42	Included, n = 34	Consented vs. included, p valuesa
Median (range)
Age	30.5 (22–45)	29.5 (22–44)	.441
Body mass index	22.5 (17.6–42.6)	22.6 (17.6–42.6)	.208
Laparoscopies for endometriosis	1 (0–10)	1 (0–10)	.729
Total gynaecologic surgeries	2 (0–10)	2 (0–10)	.843
Number (%)
Country of birth			.424
Australia	31 (74)	26 (77)
Other	11 (26)	8 (24)
Relationship status			.836
Single	7 (17)	5 (15)
In a relationship	34 (81)	28 (82)
Other	1 (2)	1 (3)
Women who had vaginal deliveries	7	5	.474

^a Mann–Whitney’s U-test.

Table 2. Previous medical and surgical interventions.

Intervention	Participants having tried, but ceasing medications prior to baseline	Participants on these medications at baseline
Medical
Hormonal
Oral contraceptive pill	19	8
LNG-IUDa	9	7
Etonogestrel depot	2	0
Oral progestins	3	2
Total	26	16
Centrally acting agents
Tricyclic	5	2
SNRIb	0	3
SSRIc	0	3
Pregabalin	2	2
Total	6	7
Analgesics
Opioids	0	2
OTC (NSAIDs/paracetamol)d	0	6
Total	0	7
Interventional
Laparoscopy for diagnosis/ excision of endometriosis		22
Hysterectomy		3
Injection of Botox™ to the pelvic floor		1
Total		22

^a Levonorgestrel intrauterine device.

^b Serotonin and norepinephrine reuptake inhibitors.

^c Selective serotonin reuptake inhibitors.

^d Over the counter drugs (nonsteroidal anti-inflammatory drugs/paracetamol).

Figure 1. VAS changes in women with reported baseline pain with at least one other completed follow-up.

A box and whisker plot graph outlining the mean VAS pain changes in participants with reported baseline pain in each pain parameter with at least one follow-up. The box and whisker plot graph describe the VAS pain scale changes from baseline to 3 month and 2 year follow-up. The X-axis shows the VAS score, and the Y-axis shows the types of pain which are dysmenorrhoea, dyspareunia, dyschezia, dysuria, low back pain, abdominal pain and non-menstrual pelvic pain. The graph demonstrates a significant reduction in dysmenorrhoea, dyschezia, low back pain and non-menstrual pelvic pain at 3 months, and a significant reduction in dyspareunia and dysmenorrhoea at 2 years.